1665-5044 1665-5044 S1665-50442019000200033 10.24875/rmn.m19000056 México México México México México México México México 00 04 2019 00 04 2019 20 2 33 41

1 2016 76 647-61 2 2015 44 e36-42 3 2017 58 1686-96 4 2017 19 553-67 5 2017 50 418-24 6 2016 18 367-83 7 2014 55 475-82 8 2017 58 512-21 9 2017 89 893-9 10 2016 57 2019-30 11 2011 33 213-20 12 2012 78 1974-80 13 2014 14 2018 15 National Institute for Health and Clinical Excellence 2012 16 2013 15 519-28 17 2013 18 1997 337 1807-12 19 2014 55 Suppl 4 Suppl 4 29-33 20 2013 22 3-8 21 2018 391 1085-96 22 2016 35 41-4 23 2007 48 1703-7 24 2010 52 988-93 25 2012 16 459-63 26 2002 3rd ed 27 2018 57 66-9 28 2006 47 1094-120 29 2013 54 551-63 30 2015 56 1185-97 31 2018 7 32 2017 2 33 2018 6 34 2013 50 1033-40 35 2015 60 365-79 36 2007 369 1000-15 37 2007 8 34 38 Levetiracetam Monotherapy Study Group 2007 68 402-8 39 2014 55 1088-98 40 2016 39 5-9 41 2011 1214 42 2003 1 43 2013 1 44 2013 8 45 2003 107 165-75 46 2006 1 47 2013 27 273-86 48 2009 4 49 2008 23 515-9 50 Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy 1998 39 952-9 51 1999 33 133-43 52 2012 83 1093-8